NBC Securities Inc. Purchases 2,672 Shares of Repligen Co. (NASDAQ:RGEN)

NBC Securities Inc. raised its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 133,600.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,674 shares of the biotechnology company's stock after acquiring an additional 2,672 shares during the period. NBC Securities Inc.'s holdings in Repligen were worth $340,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. CIBC Asset Management Inc grew its position in Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after acquiring an additional 81 shares during the period. Louisiana State Employees Retirement System lifted its stake in Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after buying an additional 100 shares during the period. Utah Retirement Systems lifted its stake in Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after buying an additional 100 shares during the period. Peapack Gladstone Financial Corp lifted its stake in Repligen by 5.2% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock valued at $301,000 after buying an additional 103 shares during the period. Finally, Signaturefd LLC lifted its stake in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Insider Activity

In other Repligen news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Repligen Price Performance

Repligen stock opened at $128.30 on Friday. The stock's fifty day moving average price is $127.27 and its two-hundred day moving average price is $143.38. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market cap of $7.21 billion, a PE ratio of -251.57, a price-to-earnings-growth ratio of 4.54 and a beta of 1.10.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. During the same quarter last year, the company earned $0.28 EPS. The company's revenue was up 10.4% on a year-over-year basis. As a group, research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RGEN shares. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a report on Tuesday, April 29th. JPMorgan Chase & Co. reduced their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Canaccord Genuity Group reduced their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average price target of $173.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.